VUDALIMAB

UNII: 4I9I5X3Z6N
Preferred Substance Name: VUDALIMAB

2329669-72-7
ANTI-PD-1/ANTI-CTLA-4 XMAB20717
ANTI-PD1/CTLA4 BISPECIFIC ANTIBODY XMAB20717
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC
PD-1 X CTLA-4 DUAL CHECKPOINT INHIBITOR XMAB20717
VUDALIMAB [INN]
VUDALIMAB [USAN]
VUDALIMAB [WHO-DD]
XMAB20717
XMAB-20717

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

About, Contact Us, Copyright, Privacy, Accessibility

U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002

U.S. Food and Drug Administration, Health & Human Services

Freedom of Information Act

VUDALIMAB

Synonyms and Mappings

Resources

Note